Melanoma Research

Papers
(The H4-Index of Melanoma Research is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study50
Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study36
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting26
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel25
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan23
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?19
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors19
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases18
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases18
CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma18
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model16
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection15
Chromosome 1p13.2 gene cluster upregulation in neuroblastoma RAS viral oncogene homolog pathogenic variant melanoma: a potential biomarker axis14
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study13
Real-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimates13
Brain metastases during follow-up of patients with resected cutaneous melanoma13
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy13
0.21303915977478